Alchemab receives Innovate UK grant for Huntington’s antibody discovery
The biotech company works with Medicines Discovery Catapult to investigate naturally protective antibodies.
Alchemab announced a Biomedical Catalyst early award grant from Innovate UK on 16 March 2021. The award supports its collaboration with Medicines Discovery Catapult on a potential disease-modifying treatment for Huntington’s disease. The announcement did not disclose the grant amount.
The research starts with antibodies identified in patients whose disease progressed more slowly than expected. Alchemab plans to characterise those antibodies and identify candidates for further development, combining its discovery platform with the catapult’s human cell models. CHDI Foundation supplies patient samples for the project.
Use of funds
Develop resilient-patient antibody programme for Huntington disease